A detailed history of Swiss National Bank transactions in Evolus, Inc. stock. As of the latest transaction made, Swiss National Bank holds 91,700 shares of EOLS stock, worth $1.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,700
Previous 102,600 10.62%
Holding current value
$1.3 Million
Previous $1.11 Million 33.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$10.66 - $17.48 $116,194 - $190,532
-10,900 Reduced 10.62%
91,700 $1.49 Million
Q2 2024

Aug 08, 2024

BUY
$10.45 - $13.76 $70,015 - $92,192
6,700 Added 6.99%
102,600 $1.11 Million
Q1 2024

May 07, 2024

BUY
$9.99 - $14.91 $60,939 - $90,951
6,100 Added 6.79%
95,900 $1.34 Million
Q4 2023

Feb 06, 2024

SELL
$7.6 - $10.53 $30,400 - $42,120
-4,000 Reduced 4.26%
89,800 $945,000
Q3 2023

Nov 08, 2023

BUY
$7.15 - $10.2 $12,155 - $17,340
1,700 Added 1.85%
93,800 $857,000
Q2 2023

Aug 09, 2023

BUY
$7.23 - $10.52 $95,436 - $138,864
13,200 Added 16.73%
92,100 $669,000
Q1 2023

May 10, 2023

SELL
$7.81 - $11.05 $71,071 - $100,555
-9,100 Reduced 10.34%
78,900 $667,000
Q4 2022

Feb 08, 2023

BUY
$6.52 - $8.95 $17,604 - $24,164
2,700 Added 3.17%
88,000 $660,000
Q2 2022

Aug 09, 2022

BUY
$10.22 - $13.94 $871,766 - $1.19 Million
85,300 New
85,300 $989,000
Q2 2020

Aug 05, 2020

SELL
$3.53 - $6.17 $160,262 - $280,118
-45,400 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$3.53 - $12.21 $6,001 - $20,757
1,700 Added 3.89%
45,400 $188,000
Q4 2019

Feb 06, 2020

BUY
$11.58 - $17.37 $242,022 - $363,033
20,900 Added 91.67%
43,700 $532,000
Q2 2019

Aug 02, 2019

BUY
$13.19 - $28.36 $300,732 - $646,608
22,800 New
22,800 $333,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $798M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.